Loading...
XNAS
NMTC
Market cap23mUSD
Jul 09, Last price  
2.75USD
1D
-8.03%
1Q
-37.36%
IPO
-96.18%
Name

Neuroone Medical Technologies Corp

Chart & Performance

D1W1MN
XNAS:NMTC chart
P/E
P/S
1.98
EPS
Div Yield, %
Shrs. gr., 5y
49.29%
Rev. gr., 5y
44.41%
Revenues
12m
+250.35%
1,1675,3989211,24977374200001,926,566178,146171,1691,952,4413,453,00312,097,692
Net income
-4m
L-70.73%
-6,044-27,604-13,960-30,554-36,244-62,863-47,775-5,058,426-6,826,775-6,781,161-13,640,160-9,948,168-9,999,613-11,859,491-12,318,110-3,605,374
CFO
-3m
L-74.23%
-5,092-27,428-13,733-25,093-26,173-30,229-21,106-2,108,073-2,827,611-5,395,957-3,425,302-8,602,826-7,519,534-12,886,874-11,011,840-2,837,272

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
IPO date
Nov 09, 2012
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT